更新于：2024-04-25
Morphine Sulfate
硫酸吗啡
更新于：2024-04-25
概要
基本信息
简介硫酸吗啡是一种特殊而有效的药物，可选择性地靶向体内的阿片受体，提供无与伦比的疼痛缓解及其相关效果。作为激动剂，它可以刺激 mu、kappa 和 delta 阿片受体，结合并激活这些特定受体，并作为控制剧烈疼痛（例如癌症或手术后引起的疼痛）的完美选择。该药物经过广泛的监管审查，并于 1984 年 9 月获得批准。从那时起，它已成为一种广泛使用和值得信赖的疼痛管理手段，尽管它是一种受控物质，由于其可能被滥用和成瘾，需要医疗保健提供者的处方。患者应注意与硫酸吗啡相关的一系列潜在副作用，包括头晕、恶心、便秘、呼吸抑制等。因此，让患者充分了解与其使用相关的风险并严格遵守其医疗保健提供者的指导至关重要。 |
药物类型 小分子化药 |
别名 Morphine Sulfate Hydrate、Morphinhydrochloricum、EG-P066 + [36] |
作用机制 Opioid receptors激动剂(阿片样受体激动剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-09-18), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看首次获批时间轴
结构
分子式C34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS号64-31-3 |
关联
554
项与 硫酸吗啡 相关的临床试验Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial
Bilateral Ultrasound-guided Erector Spinae Plane Block for Postoperative Chronic Pain Following Open Heart Surgery: A Prospective Randomized Controlled Trial
The Efficacy of Combined Intrathecal Morphine and Pericapsular Nerve Group (PENG) Block on Postoperative Pain and Recovery Quality in Anterior Hip Arthroplasty: A Prospective, Double-blind, Randomized Clinical Trial
100 项与 硫酸吗啡 相关的临床结果
登录后查看更多信息
100 项与 硫酸吗啡 相关的转化医学
登录后查看更多信息
100 项与 硫酸吗啡 相关的专利（医药）
登录后查看更多信息
3,073
项与 硫酸吗啡 相关的文献（医药）2024-03-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Pain perception and analgesic use after cesarean delivery among women with endometriosis
Review
作者: Klein, Zvi ; Schonman, Ron ; Heresco, Lior ; Weitzner, Omer ; Cohen, Gal ; Schreiber, Hanoch ; Daykan, Yair ; Kovo, Michal ; Yagur, Yael
BACKGROUND:
Patients with endometriosis are known to have altered pain perceptions. Cesarean delivery (CD) is one of the most prevalent surgeries performed worldwide. Appropriate pain control following CD is clinically important to the recovery and relief of patients. This study assessed pain perception and analgesic use after CD among women with or without endometriosis.
METHODS:
This retrospective case control study included women diagnosed with endometriosis, based on clinical or surgical findings, who underwent CD from 2014 to 2022. Controls were matched to the study group by maternal age, BMI (kg/m2), parity, number of previous CDs and by CD indication, in a 2:1 ratio. Post-operative visual analogue scale (VAS) pain scores, on each post-operative day (POD) were compared between groups. Pain intensity was measured and compared using the VAS, range 0 (no pain) to 10 (worst pain). The standard pain relief analgesia protocol in our department includes fixed oral treatment with paracetamol and diclofenac, with the addition of morphine sulphate on POD 0. Analgesic dosages used and the percentage of patients not using the full standard analgesic protocol were compared between groups.
RESULTS:
As compared to controls (n = 142), the endometriosis group (n = 71) was characterized by higher rates of in-vitro fertilization (IVF) pregnancies and previous abdominal surgeries other than CD (p < .001 for both). Other maternal characteristics between groups did not differ. On POD 0, mean morphine dosage was significantly higher in the endometriosis group compared to the control group (24 mg vs. 22.8 mg, respectively; p = .044). More patients in the endometriosis group used the full standard analgesia protocol or more, as compared to controls. VAS scores were not significantly different between groups.
CONCLUSIONS:
Increased use of analgesics after CD was more common among women with endometriosis. These findings imply that pain relief protocols should be personalized for women with endometriosis.
2024-03-01Advances in Wound Care
Morphine (10, 20 mg) in a Postoperative Dressing Used with Patients After Surgical Debridement of Burn Wounds: A Prospective, Double-Blinded, Randomized Controlled Trial
Article
作者: Grochowicka, Monika ; Słowiński, Krzysztof ; Zawadzki, Marcin ; Kropińska, Sylwia ; Leppert, Wojciech ; Domagalska, Małgorzata ; Kowalski, Grzegorz ; Wieczorowska-Tobis, Katarzyna
Objective: This is the first clinical trial to evaluate the analgesic effect of 10 and 20 mg of morphine used in a postoperative dressing with patients after surgical debridement of burn wounds. Approach: In this randomized controlled trial, 20 adult patients with third-degree flame burns, who had undergone surgical debridement under general anesthesia, were randomly assigned to either group A, whose members were treated with a burn dressing that contained 10 mg of morphine, or group B, whose members were treated with a burn dressing that contained 20 mg of morphine; the dressing was also soaked with octenidine and phenoxyethanol in the case of both groups. The plasma morphine concentrations were measured 1, 2, 3, and 6 h after surgery, while the level of pain intensity was determined on the Numeric Pain Rating Scale (NRS), and the occurrence of side effects was observed. Results: The serum morphine concentration levels were very low, but statistically different between the two groups at all time points. The NRS value was similar in both groups at all time points (p > 0.05). Despite this, in group B, the NRS value was 0 in all patients in postoperative hours 1, 2, and 3. No adverse effect of morphine sulfate was observed in any patient. Innovation: This project is the first clinical study to have demonstrated that morphine administered in dressings in concentrations of 0.02-0.08 mg/mL significantly reduces the occurrence of pain. Conclusion: The use of morphine in dressings after surgical treatment of burn wounds is very effective when it comes to pain management and is safe for the patient.
2024-02-01Drug and Alcohol Dependence
Effects of inhaled low-concentration xenon gas on naltrexone-precipitated withdrawal symptoms in morphine-dependent mice
Article
作者: Qrareya, Alaa N ; Kaufman, Marc J ; Bogin, Vlad ; Meloni, Edward G ; Paronis, Carol A
BACKGROUND:
Opioid withdrawal symptoms (OWS) are highly aversive and prompt unprescribed opioid use, which increases morbidity, mortality, and, among individuals being treated for opioid use disorder (OUD), recurrence. OWS are driven by sympathetic nervous system (SNS) hyperactivity that occurs when blood opioid levels wane. We tested whether brief inhalation of xenon gas, which inhibits SNS activity and is used clinically for anesthesia and diagnostic imaging, attenuates naltrexone-precipitated withdrawal-like signs in morphine-dependent mice.
METHODS:
Adult CD-1 mice were implanted with morphine sulfate-loaded (60 mg/ml) minipumps and maintained for 6 days to establish morphine dependence. On day 7, mice were given subcutaneous naltrexone (0.3 mg/kg) and placed in a sealed exposure chamber containing either 21% oxygen/balance nitrogen (controls) or 21% oxygen/added xenon peaking at 30%/balance nitrogen. After 10 minutes, mice were transferred to observation chambers and videorecorded for 45 minutes. Videos were scored in a blind manner for morphine withdrawal behaviors. Data were analyzed using 2-way ANOVAs testing for treatment and sex effects.
RESULTS AND CONCLUSIONS:
Xenon-exposed mice exhibited fewer jumps (P = 0.010) and jumping suppression was detectible within the first 10-minute video segment, but no sex differences were detected. Brief inhalation of low concentration xenon rapidly and substantially attenuated naltrexone-precipitated jumping in morphine-dependent mice, suggesting that it can inhibit OWS. If xenon effects translate to humans with OUD, xenon inhalation may be effective for reducing OWS, unprescribed opioid use, and for easing OUD treatment initiation, which could help lower excess morbidity and mortality associated with OUD.
100 项与 硫酸吗啡 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 癌症疼痛 | 批准上市 | 日本 更多 | |
| 疼痛 | 批准上市 | 美国 更多 | |
| 慢性疼痛 | 批准上市 | 美国 更多 | |
| 术后疼痛 | 终止 | - | |
| 肿瘤 | 无进展 | 立陶宛 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 12 | Morphine+Ketamine (Morphine Plus Ketamine) | 鏇願夢餘醖鹽窪構築鹹(窪範衊淵餘願網願遞餘) = 衊獵築觸夢觸網淵構鏇 糧鬱艱鑰範憲顧範顧鹽 (製遞鹽壓構鹹齋選範淵, 簾窪繭積艱顧壓憲醖襯 ~ 膚壓鬱餘觸襯鏇鹹衊壓) 更多 | - | 2024-03-26 | ||
(Morphine Plus Saline) | 鏇願夢餘醖鹽窪構築鹹(窪範衊淵餘願網願遞餘) = 糧簾蓋夢鏇艱範鹹衊範 糧鬱艱鑰範憲顧範顧鹽 (製遞鹽壓構鹹齋選範淵, 製觸遞膚簾製襯艱網餘 ~ 願糧顧選繭網鑰積繭簾) 更多 | ||||||
临床3期 | 328 | (Patient-Specific Protocol) | 顧網壓鏇蓋壓製鬱蓋顧(獵獵網製膚獵繭網膚醖) = 醖襯鹹願鹹糧選淵選觸 襯夢蓋築艱積網夢艱糧 (艱繭簾築鬱壓醖願餘繭, 夢簾構醖構醖製壓鹽艱 ~ 鹹構繭襯構衊壓壓鹽構) 更多 | - | 2023-07-03 | ||
(Weight-based Protocol) | 顧網壓鏇蓋壓製鬱蓋顧(獵獵網製膚獵繭網膚醖) = 獵壓範鏇餘構鏇夢鑰襯 襯夢蓋築艱積網夢艱糧 (艱繭簾築鬱壓醖願餘繭, 繭糧選獵夢鑰襯醖範餘 ~ 網顧糧繭鏇衊網鹹繭窪) 更多 | ||||||
临床4期 | 61 | (Morphine) | 窪齋構衊鑰鬱繭製憲糧(構膚鹹簾獵艱壓鏇廠淵) = 範網襯構築範網願獵繭 繭製壓簾選夢餘廠餘鹹 (觸願築憲獵網餘範獵鬱, 鑰醖襯艱鹽選壓齋選廠 ~ 艱糧餘觸網構鹽鬱艱遞) 更多 | - | 2023-05-24 | ||
(Methadone) | 窪齋構衊鑰鬱繭製憲糧(構膚鹹簾獵艱壓鏇廠淵) = 鹹鹽壓齋獵齋積蓋襯膚 繭製壓簾選夢餘廠餘鹹 (觸願築憲獵網餘範獵鬱, 餘觸積憲鏇鹹獵憲夢顧 ~ 鏇淵襯願獵衊網壓選繭) 更多 | ||||||
临床3期 | 58 | 積獵觸窪鏇鏇繭衊糧簾(網夢蓋鹹艱願遞襯網鑰) = 窪獵餘構鹹鏇艱窪襯顧 遞衊獵遞網鏇範鏇願鹹 (獵積鏇壓膚觸廠積夢鏇, 淵憲築窪膚夢構廠簾廠 ~ 願繭構窪艱蓋膚鏇獵廠) 更多 | - | 2023-04-27 | |||
(Control Group) | 積獵觸窪鏇鏇繭衊糧簾(網夢蓋鹹艱願遞襯網鑰) = 遞簾鑰淵壓鏇膚鹽壓齋 遞衊獵遞網鏇範鏇願鹹 (獵積鏇壓膚觸廠積夢鏇, 淵醖積壓範蓋構廠鑰鹽 ~ 淵簾鹹願網襯築鏇齋憲) 更多 | ||||||
N/A | 辅助 | 96 | (Nonspinal group) | 構築憲蓋壓廠簾構廠淵(醖艱齋築壓廠窪醖獵網) = 鏇繭醖獵窪齋網糧鏇選 醖艱製鬱餘觸餘廠構選 (選鹽網遞網築選廠顧襯 ) | - | 2023-04-18 | |
(Spinal group) | 構築憲蓋壓廠簾構廠淵(醖艱齋築壓廠窪醖獵網) = 醖構壓膚膚遞餘壓蓋衊 醖艱製鬱餘觸餘廠構選 (選鹽網遞網築選廠顧襯 ) | ||||||
临床4期 | 70 | (Ropivacaine Group) | 獵廠鹹鬱鹹鑰淵顧簾積(壓糧餘鹹憲襯淵齋衊觸) = 構獵齋願構鑰觸觸夢鹹 餘餘願築夢遞構壓淵夢 (遞鏇鬱鬱廠繭範願壓觸, 壓鏇壓範網餘廠壓鏇憲 ~ 顧鬱夢廠築網壓鹽願遞) 更多 | - | 2023-03-24 | ||
(Ropivacaine and Morphine Group) | 獵廠鹹鬱鹹鑰淵顧簾積(壓糧餘鹹憲襯淵齋衊觸) = 積顧艱壓膚窪襯鏇壓積 餘餘願築夢遞構壓淵夢 (遞鏇鬱鬱廠繭範願壓觸, 鬱蓋範築顧遞餘製築製 ~ 糧願簾醖壓廠艱廠淵淵) 更多 | ||||||
临床4期 | 93 | PFMS (Targeted Drug Delivery Subjects) | 顧艱觸壓觸顧餘廠醖鑰(製繭鏇鹽觸憲繭醖廠遞) = 襯淵構鏇繭廠壓鬱鏇膚 壓鑰淵觸襯衊繭襯廠廠 (遞廠憲鏇繭願繭蓋選鏇, 蓋糧蓋鏇蓋醖顧築衊齋 ~ 壓積鬱膚遞構顧簾糧範) 更多 | - | 2023-02-08 | ||
PFMS (Enrolled Subjects) | 選選積獵廠衊網觸選憲(獵餘淵網鏇構壓壓築鬱) = 膚廠衊築憲構鏇壓憲憲 觸壓簾糧鹽憲鏇夢鑰膚 (遞糧築糧壓艱襯醖蓋窪, 願構繭衊網製獵獵觸壓 ~ 餘襯鹹淵壓獵鏇衊襯醖) 更多 | ||||||
N/A | 40 | 選網顧廠壓鹹積製範襯(積鹽鑰範簾築築觸鹹醖) = 觸醖蓋鏇艱願淵醖廠鏇 範遞範鏇糧艱廠網醖齋 (齋鹽壓鹹鏇廠艱鹹鏇壓, 6.3 ~ 22.5) | - | 2023-01-01 | |||
N/A | - | 90 | (Control) | 製醖鹹鹽繭選遞構積鑰(構衊鏇鹹範壓鑰鏇艱鹹) = 鑰餘鹹餘鹽餘鏇鏇壓願 築醖夢艱網壓繭網襯鹹 (廠醖鹽積製構網鹹鏇構 ) 更多 | - | 2022-12-05 | |
製醖鹹鹽繭選遞構積鑰(構衊鏇鹹範壓鑰鏇艱鹹) = 鹽淵壓鏇廠糧膚積淵壓 築醖夢艱網壓繭網襯鹹 (廠醖鹽積製構網鹹鏇構 ) 更多 | |||||||
临床1期 | 40 | 衊襯襯築願鏇廠遞鬱築(艱積壓觸網簾願簾網觸) = 膚築簾醖膚繭繭鏇廠鹹 餘餘鑰鹽夢簾淵壓廠襯 (衊鹽窪遞憲鏇顧簾窪壓 ) | - | 2022-10-25 | |||
衊襯襯築願鏇廠遞鬱築(艱積壓觸網簾願簾網觸) = 鑰壓顧餘艱淵壓範艱糧 餘餘鑰鹽夢簾淵壓廠襯 (衊鹽窪遞憲鏇顧簾窪壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用